Dra. Teresa Garcia Miralles
|
 |
[Índice] [Introducción] [Facts. 1ª Gen.] [Facts. 2ª Gen.] [Iconografía] [Conclusiones] [Protocolo] [Bibliografía] |
1.- Wold Health Organization . Cancer Incidence in five continents. Vol IV
2.- Connelly PJ, Alberhasky RC, Chistopherson WM. Carcinoma of the endometrium III. Analysis of 865 cases of adenocarcinoma and adenoacantoma. Obstet Gynecol 1982;59:569-576.
3.-Valsecchi L, Mangili G, Frigerio L, Spagnolo DL, De Sanctis L, Ferrari A. Reability of preoperative evaluation of prognostic factors in endometrial carcinoma. Int J Gynarcol Obstet 1997;59 (1):35-39.
4.- Mikuta JJ.Internacional Federation of Gynecology and Obstetric Staging of Endometrial Cancer.Cancer 1988;71:1460-1470..
5.- Cowles TA, Magrina JF, Masterson B et al. Comparison of Clinical and Surgical Staging in patients with endometrial carcinoma. Obstet Gynecol 1985;66:413-418.
6.-Dallenbach-Hellweg G. Histopatology of the endometrium . 4º edicion, Berlin Heidelberg New York London Paris Tokio:Springer-Verlag, 1987:226-275.
7.- Silverberg SG, Kurman RJ.Tumors of the Uterine Corpus and Gestational Trophoblastic Disease. 3ª serie. AFIP Washington 1992: 47-48.
8.- Nordstrom B, Strang P, Lindgren A, Bergstrom R, Tribukait B. Carcinoma of the endometrium: do the nuclear grade and DNA ploidy provide more prognostic information that do the FIGO and WHO classification?. Int J Gynecol Pathol 1996;15(3):191-201.
9.- Sorbe B, Risberg B, Frankendal B. DNA ploidy, morphometry and nuclear grade as prognostic factors in endometrial carcinoma. Gynecol Oncol 1990; 38: 22-27.
10.- Sorbe b, Risberg B. Prognostic importance of the nuclear protein p53 and RB in conjuntion with DNA, nuclear morphometry and grading in endometrial carcinoma. Int J Gynecol Cancer 1997;7:34-41.
11.- ChanbersJT, Carcangiu ML, Voynick IM, Schwatz PE.Inmunohistochemical evaluation of Estrogen and Progesterone Receptor Content in 183 Patients with Endometrial Carcinoma.Am J Clin Pathol 1990;94:255-260.
12.-Kohlberger PD, Kieback DG, Breitenecker F, Loesch A, Gitsch G, Kainz C, Breitenecker G. Epithelial and stroma estrogen and progesterone receptor expression in endometrial cancer: true color computer-assisted image analysis versus subjective scoring.Gynecol Oncol 1997;64 (3):404-410.
13.- Nyholm HC, Christensen IJ, Nielsen AL. Progesterone receptor level independently predict survival in endometrial adenocarcinoma. Gynecol Oncol 1995;59 (3):347-351.
14.- Utaaker E, Iversen OE, Skaarland E. The distribution and prognostic implication of steroid receptors in endometrial carcinoma. Gynecol Oncol 1987;28 (1):89-100.
15.- Sasco AJ. Endometrial cancer following breast cancer: Effect of tamoxifen and castration by radiotherapy. Epidemiology 1996,7 (1):9-13.
16.-Cohen I et al. Gynecologic tumors in tamoxifen-treated woman with breast cancer. Obstet Gynecol 1994; 83 (1): 158-159.
17.-Dallenbach-Hellweg G, Hahn U, Schmidt D.Morphologic endometrium changes with tamoxifen. Zentralbl Gynakol 1996;118(6):365-369.
18.- Kihana T, Hamada K, Inoue Y. Mutation and allelic loss of the p53 gene in endometrial carcinoma. Cancer 1995;76:72-78.
19.- Prat J, Oliva E, Lerma E et al. Uterine papillary serous expression and DNA content. Cancer 1994;74:1778-1783.
20.-Geisler JP, Wiemann MC, Zhou Z, Miller GA, Geisler HE. P53 as a prognostic indicator in endometrial cancer. Gynecol Oncol 1996;61(2):245-248.
21.- Hamel NW, Sebo TJ, Wilson TO, Keeney GL, Roche PC, Suman VJ, Hu TC, Podratz KC. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma.Gynecol Oncol 1996;62(2);192-198.
22.- Caduff RF, Johnston CM, Frank TS. Mutation of the Ki-ras oncogen in carcinoma of the endometrium. Am J Pathol 1995;146(1):182-188.
23.- Mizuuchi H, Nasim S, Kudo R, Silverberg SG, Greenhouse S, Garrett CT. Clinical implications of K-ras mutations in malignant epithelial tumorss of the endometrium. Cancer Res 1992 ;52 (10): 2777-2781.
24.- Semczuk A, Berbec H, Kostuch M, Kotarski J, Wojcieroswski J. Detection of K-ras mutations in cancerous lesions of human endometrium.Eur J Gynaecol Oncol 1997;18(1):80-83.
25.-Esteller M, Garcia A, Matinez Palones JM, Xercavins J, Reventos J. The clinicaopathological significance of K-ras point mutation and gene amplification en endometrial cancer. Eur J Cancer 1997;33(10):1572-1577.
26.-Hironobu Sasano, Keiko Watanabe, Kiyoshi Ito, Shinji Sato, Akira Yajima.New Concepts in the diagnosis qand Prognosis of endometrial Carcinoma. Pathology Annuals 1994:31-49.
27.-Sato S.Evaluation of the degree of biological behavior in endometrial hiperplasia and endometrial carcinoma: An investigation of proliferative activity, oncogene, and extracellular matrix. Acta Obst Gynaecol Jpn 1993;45:776-1780.
28.-Riben MW, Malfetano JH, Nazeer T, Muraca PJ, Ambros RA, Ross JS. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma. Mod Pathol 1997;10(8):823-831.
29.-Cirisano FD, Karlan BY. The role of the HER-2/neu oncogene in gynecilogic cancers.J Soc Gynecol Investig.1996;3(3):99-105.
30.-Lindahl B, Einarsdottir M, Iosif C, Ranstam J, Willen R.Endometrial carcinoma:results of primary surgery on FIGO stages IA-Ic and predictive value of histopatological parameters.Anticancer Res 1997;17(3C):2297-2302.
31.-Sato S, Ito K, Yajima A .Expression of c-myc, epidermal growth factor receptor and c-erb-B2 in human endometrial carcinoma and cervical adenocarcinoma. Tohoku J Exp Med 1991;165:139-143.
32.-Britton LC, Wilson TO, Gffey TA et al. Flow Cytometry DNA analysis of stage I endometrial carcinoma. Gynecol Oncol 1989;34:317-322.
33.- Thorton J, Quirke P, Wells M. Flow cytometry of normal, hiperplastic and malignant human endometrium. A study of ploidy and proliferative indices including comparison with in vitro S-phase labeling. Am J Obst Gynecol 1989;161:487-492.
34.- Iversen OE. Flow cytometric deoxyribonucleic acid index: a prognostic factor in endometrial carcinomaAm J Obstet Gynecol 1986;155:770-776.
35.- Tsou Kwan Chung, Dai Hwa, Varello M, et al. Flow cytometric DNA and 5 nucleotide phosphodiesterase in endometrium. Cancer 1985; 56:2340-2347.
36.- Sorbe B, Risberg B, Frankendel B. DNA ploidy, morphometry and nuclear grade as prognostic factors in endometrial carcinoma. Gynecol Oncol 1990;38:22-27.
37.- Kaleli et al. Strong prognostic variable in endometrial carcinoma. Cancer 1997;79(5) 943-951.
38.- Berstein Lm, Bakhidze Ev, Evtushenko TP et al. Estrogen content and DNA unwinding in tumor and normal endometrial tissue of aging endometrial cancer patients.Mutat Res.1996;356(2):203-208.
39.- Nauman G, Kohler U, Nenning H.Relation between various DNA parameters and degree of malignancy in endometrial carcinoma. Arch Gynecol Obstet 1996;258(3):113-117.
40.- Sato s, Tanouguchi K, Tase T, Vajima A. Flow cytometric DNA analysis of abnormal endometrium.Tohoku J Exp Med 1996;178(2):199-202.
[Índice] [Introducción] [Facts. 1ª Gen.] [Facts. 2ª Gen.] [Iconografía] [Conclusiones] [Protocolo] [Bibliografía] |
